Pro-inflammatory cytokine production and nitric oxide

Pro-inflammatory cytokine production and nitric oxide represents a coordinated biological response typically mediated by the innate immune system in response to stimuli such as pathogens or tissue injury. This process involves the synthesis and secretion of signaling proteins like Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-6 (IL-6), which orchestrate systemic inflammation (Source: Nature Reviews Immunology, PMID: 11907593). Simultaneously, nitric oxide (NO) is produced by the enzyme inducible nitric oxide synthase (iNOS) to assist in vasodilation and the destruction of pathogens. While essential for host defense, the dysregulation of these mediators is a hallmark of various inflammatory, autoimmune, and neurodegenerative diseases (Source: Frontiers in Pharmacology, PMID: 29403371). In pharmacological research, this phrase is frequently used as a phenotypic readout or assay endpoint rather than a single molecular target. Drugs that modulate this response typically act on upstream signaling pathways, such as the NF-kappaB or JAK/STAT pathways, or directly neutralize the cytokines themselves (Source: Journal of Inflammation Research, PMID: 30122977). Consequently, while it is a critical therapeutic focus, it represents a physiological outcome of multiple interacting molecular targets rather than a single druggable entity.

Other names

Inflammatory mediator releaseCytokine and NO synthesisPro-inflammatory response

Inhibition of upstream signaling pathways (e.g., NF-κB, MAPK, JAK/STAT) or direct neutralization of cytokines and inhibition of nitric oxide synthase enzymes.